This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

Cyclic adenosine monophosphate (cAMP); cell division cycle 25B
(CDC25B); melanocortin 1 receptor (MC1R)

Cell culture studies suggest targeting the MC1R-cAMP-CDC25B signaling pathway could help treat melanoma. In a panel of human melanoma cell lines, activators of MC1R or cAMP signaling inhibited cell cycle progression compared with vehicle. In the cell lines, MC1R- and cAMP-mediated inhibition of cell cycle progression was dependent on inhibitory phosphorylation of CDC25B. Next steps could include screening for and evaluating pharmacological inhibitors of CDC25B in melanoma models.

SciBX 6(33); doi:10.1038/scibx.2013.888
Published online Aug. 29, 2013

Patent and licensing status unavailable

Lyons, J. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 1, 2013;
doi:10.1073/pnas.1201917110
Contact: Frank McCormick, University of California, San Francisco, Calif.
e-mail:

mccormick@cc.ucsf.edu